We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q4 CY2024, with sales up 95.1% year on year to $481.1 million. On top of that, next quarter’s revenue ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Hims & Hers delivered Q4 2024 earnings that saw the stock sell off nearly 20% after hours. Find out why I rate HIMS stock a ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

We recently compiled a list of the Jim Cramer’s Game Plan: 17 Stocks in Focus. In this article, we are going to take a look ...

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. About This ...

Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.